Bristol-Myers to buy Medarex for $2.4 billion

NEW YORK (Reuters) – U.S. drugmaker Bristol-Myers Squibb Co on Wednesday said it will pay $2.4 billion to acquire Medarex Inc , a biotechnology company that has been helping it develop a promising treatment for melanoma since 2005.

Leave a Reply